TMB Capital Partners LLC Invests $2.23 Million in CME Group Inc. $CME

TMB Capital Partners LLC acquired a new stake in CME Group Inc. (NASDAQ:CME) in the fourth quarter, Holdings Channel reports. The institutional investor acquired 8,167 shares of the financial services provider’s stock, valued at approximately $2,230,000.

A number of other institutional investors also recently made changes to their positions in the business. West Family Investments Inc. raised its position in CME Group by 1.2% in the 3rd quarter. West Family Investments Inc. now owns 3,062 shares of the financial services provider’s stock worth $827,000 after purchasing an additional 37 shares during the period. Asset Dedication LLC boosted its position in CME Group by 64.9% during the fourth quarter. Asset Dedication LLC now owns 94 shares of the financial services provider’s stock valued at $26,000 after buying an additional 37 shares during the period. Northwestern Mutual Investment Management Company LLC boosted its position in CME Group by 0.3% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 11,523 shares of the financial services provider’s stock valued at $3,147,000 after buying an additional 37 shares during the period. Rehmann Capital Advisory Group grew its stake in shares of CME Group by 4.3% during the third quarter. Rehmann Capital Advisory Group now owns 898 shares of the financial services provider’s stock valued at $243,000 after buying an additional 37 shares during the last quarter. Finally, 1248 Management LLC grew its stake in shares of CME Group by 26.8% during the third quarter. 1248 Management LLC now owns 180 shares of the financial services provider’s stock valued at $49,000 after buying an additional 38 shares during the last quarter. Hedge funds and other institutional investors own 87.75% of the company’s stock.

CME Group News Summary

Here are the key news stories impacting CME Group this week:

• Neutral Sentiment: CME announced a planned CEO succession: longtime chief Terry Duffy will step down in March 2027 and transition to executive chairman, while President and CFO Lynne Fitzpatrick will become CEO. The move also makes Fitzpatrick CME’s first woman chief executive, which supports continuity but adds some near-term uncertainty around the handoff. Article Title
• Neutral Sentiment: The company also highlighted its long-term leadership change in multiple interviews and reports, which may reassure investors that the transition is orderly rather than sudden. Article Title
• Negative Sentiment: CME said it plans to sue the CFTC over approval of crypto perpetual futures, arguing the regulator is improperly treating these products as swaps rather than futures. The legal fight raises regulatory risk and could create uncertainty around CME’s crypto derivatives strategy. Article Title
• Negative Sentiment: Several headlines repeated the lawsuit plan, suggesting the issue is the main driver of today’s weakness as investors focus on possible friction with regulators and the implications for future product approvals. Article Title

Insider Buying and Selling

In related news, CEO Terrence A. Duffy sold 35,000 shares of the company’s stock in a transaction that occurred on Friday, May 15th. The stock was sold at an average price of $298.51, for a total transaction of $10,447,850.00. Following the completion of the transaction, the chief executive officer owned 55,630 shares in the company, valued at $16,606,111.30. This represents a 38.62% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Hilda Harris Piell sold 5,753 shares of the firm’s stock in a transaction on Monday, May 18th. The stock was sold at an average price of $304.63, for a total value of $1,752,536.39. Following the completion of the sale, the insider directly owned 27,702 shares of the company’s stock, valued at $8,438,860.26. The trade was a 17.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 0.30% of the stock is currently owned by company insiders.

CME Group Stock Performance

Shares of NASDAQ:CME opened at $246.38 on Friday. The company has a market cap of $89.28 billion, a price-to-earnings ratio of 21.02, a price-to-earnings-growth ratio of 2.82 and a beta of 0.21. The company has a 50-day moving average price of $280.74 and a 200-day moving average price of $287.50. The company has a current ratio of 1.02, a quick ratio of 1.02 and a debt-to-equity ratio of 0.13. CME Group Inc. has a 12 month low of $244.56 and a 12 month high of $329.16.

CME Group (NASDAQ:CME) last posted its earnings results on Wednesday, April 22nd. The financial services provider reported $3.36 earnings per share for the quarter, topping analysts’ consensus estimates of $3.11 by $0.25. The company had revenue of $1.88 billion during the quarter, compared to analyst estimates of $1.77 billion. CME Group had a net margin of 63.19% and a return on equity of 15.42%. CME Group’s revenue for the quarter was up 14.5% on a year-over-year basis. During the same period in the prior year, the business posted $2.80 earnings per share. As a group, equities analysts anticipate that CME Group Inc. will post 12.28 EPS for the current year.

CME Group Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Shareholders of record on Tuesday, June 9th will be issued a $1.30 dividend. The ex-dividend date is Tuesday, June 9th. This represents a $5.20 annualized dividend and a yield of 2.1%. CME Group’s dividend payout ratio (DPR) is 44.37%.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on the company. Deutsche Bank Aktiengesellschaft lowered their target price on CME Group from $342.00 to $322.00 and set a “buy” rating for the company in a research note on Thursday, April 23rd. The Goldman Sachs Group reduced their price target on CME Group from $275.00 to $267.00 and set a “sell” rating on the stock in a research report on Thursday, April 23rd. Morgan Stanley decreased their price target on CME Group from $362.00 to $353.00 and set an “overweight” rating on the stock in a research note on Thursday, April 23rd. Keefe, Bruyette & Woods upgraded CME Group from a “market perform” rating to an “outperform” rating and set a $305.00 price objective for the company in a research report on Thursday. Finally, Rothschild & Co Redburn raised CME Group from a “neutral” rating to a “buy” rating and increased their price objective for the company from $316.00 to $323.00 in a research note on Thursday, June 11th. Twelve research analysts have rated the stock with a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, CME Group presently has a consensus rating of “Moderate Buy” and a consensus price target of $305.18.

About CME Group

CME Group Inc is a global markets company that operates some of the world’s largest and most liquid derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX) and COMEX. The firm offers futures and options contracts across a broad range of asset classes — including interest rates, equity indexes, foreign exchange, energy, agricultural commodities and metals — and serves a diverse client base of institutional investors, commercial hedgers, brokers and retail participants.

The company’s core services include electronic trading on the CME Globex platform, central clearing through CME Clearing, and distribution of market data, indexes and analytics.